S0360090
(RS)-Selegiline hydrochloride
European Pharmacopoeia (EP) Reference Standard
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Fórmula empírica (notación de Hill):
C13H17N · HCl
Número de CAS:
Peso molecular:
223.74
UNSPSC Code:
41116107
NACRES:
NA.24
Productos recomendados
grade
pharmaceutical primary standard
API family
selegiline
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
InChI
1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H
InChI key
IYETZZCWLLUHIJ-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
(RS)-Selegiline hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
related product
Referencia del producto
Descripción
Precios
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
Lo sentimos, en este momento no disponemos de COAs para este producto en línea.
Si necesita más asistencia, póngase en contacto con Atención al cliente
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Chuanjun Lu et al.
European journal of medicinal chemistry, 62, 745-753 (2013-03-05)
A novel series of tacrine-selegiline hybrids was synthesised and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B). The results demonstrate that most of the synthesised compounds exhibit high inhibitory activity. Among these compounds, compound 8g provided
W A Baumgartner et al.
Medical hypotheses, 81(4), 720-728 (2013-08-21)
Numerous mutations in over 100 rod genes are the well-established cause of apoptotic death of these cells and development of night blindness in retinitis pigmentosa (RP). Cone death is either concomitant or follows rod death with resultant loss of critical
Thomas Müller et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(5), 761-765 (2012-12-01)
The objective of this study is to demonstrate that application of rasagiline instead of selegiline with concomitant determination of L-amphetamine and L-methamphetamine in plasma is safe and well tolerated and influences sleep, mood, and motor behavior in patients with Parkinson's
Makoto Naoi et al.
Expert review of neurotherapeutics, 13(6), 671-684 (2013-06-07)
In Parkinson's disease, cell death of dopamine neurons in the substantia nigra progresses and neuroprotective therapy is required to halt neuronal loss. In cellular and animal models, selegiline [(-)deprenyl] and rasagiline, inhibitors of type B monoamine oxidase (MAO)-B, protect neuronal
Qing Zhao et al.
International journal of molecular medicine, 32(4), 883-891 (2013-07-24)
The monoamine oxidase type-B (MAO-B) inhibitor, selegiline, is often recommended as a first-line treatment for Parkinson's disease (PD) and has been shwon to possess neuroprotective effects. The aim of the present study was to determine whether selegiline increases the levels
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico